RetinalGeniX™ Imaging System (RIS)

A 200-degree FOV ophthalmic imaging camera screening device. The device would be affordable and easy to use by not only Ophthalmologists, Optometrists, Opticians and eye care professionals but by all other Medical Specialties, as well, to prevent blindness. General Practitioners, Pediatricians, Hospitals, Schools, Outpatient facilities and Assisted Living facilities would be included.

The retinal screening imaging device is fast, efficient and easy to operate without dilation to screen the masses. Diabetic Maculopathy (DM) in the U.S. affects 30 Million patients of which 23 Million have been diagnosed with another 7 Million unaware of the disorder. There are 88 Million pre-diabetics under the age of 65 and 10% of the workforce over age 40 have retinal diabetic changes that can lead to diabetes.

Announcing the Retinal™GeniX Imaging System

The Retinal™GeniX Imaging System (RIS) is intended to provide the next generation of cost-effective, ultra-wide imaging technologies to examine the periphery of the Retina, at up to a 200° field of view, to detect early signs of diabetic retinopathy without having to dilate the patient's pupil.

A normal retina with an ultra-wide field-of-view contains the smallest vessels in the body ►►►

Understanding the early signs of diabetic retinopathy:

The central area of this photo shows white light from the camera reflection. There are tiny, light blots or spots farther out from the fovea/macula or center and indicate early signs of diabetic retinopathy. Those spots are small hemorrhages.

At this stage, often diabetes is diagnosed and treatment for both the body and the eye can be prescribed to preserve sight.

A retina with first signs of diabetic retinopathy  ►►►

Image credits: Lawrence A. Yannuzzi, MD

Target: Diabetic Maculopathy, Diabetic Retinopathy, Neurological disease (Alzheimer’s by inclusion of beta amyloids in the periphery).

Because it offers artificial intelligence and automated diagnostic capabilities, the RetinalGeniX Imaging System will require a 510(k) FDA clearance, a process that is usually 6-9 months.

Both the RetinalGeniX Imaging System and the Patient Home Monitoring and Physician Alert System are patented, proprietary, and first to market.

Factual Summary justifying the need for the RetinalGeniX Imaging System and the Patient Home Monitoring and Physician Alert System.

  • The most feared complication of DM is Blindness. Worldwide 500 Million patients are afflicted with Diabetic Maculopathy.
  • There are insufficient eye care professionals worldwide to screen, examine, diagnose, and treat the current load of Diabetic patients.
  • Obesity and Diabetes are associated with over One Billion afflicted with obesity alone and 500 Million with DM alone, worldwide with no end in sight!
  • The economics of the need to effectively screen patients for DM and prevent blindness are staggering.